ALOPECIA AREATA

This early-stage study is testing an experimental drug called DR-01 in adults with alopecia areata (hair loss) or vitiligo (skin depigmentation). The main goal is to check the drug's safety and see if it shows any signs of helping regrow hair or restore skin color. Researchers wi…

This study is testing an investigational drug called FB102 for people with severe to very severe alopecia areata, a condition that causes sudden hair loss. About 32 participants will be randomly assigned to receive either FB102 or a placebo (an inactive substance) to see if the d…

This study is testing a new laser device called PALLAS for treating skin conditions that often improve with UV light, including vitiligo, psoriasis, alopecia areata, and eczema. About 50 participants will receive targeted UVB laser treatments twice a week for up to three months. …

This study is testing whether transplanting healthy gut bacteria from a donor can help regrow hair in people with alopecia areata, an autoimmune condition that causes hair loss. Researchers will enroll 40 adults with moderate to severe hair loss to see if changing the gut microbi…

This study is testing if a daily pill called Abrocitinib can help control eczema (atopic dermatitis) and patchy hair loss (alopecia areata) in people with Down Syndrome. It will enroll 56 participants aged 12 and older. The goal is to see if the treatment is safe and effective at…

This study is testing whether a daily pill called upadacitinib can help regrow hair in people with severe alopecia areata, an autoimmune condition that causes patchy or total hair loss. It will involve about 123 teenagers and adults in Japan who have lost at least 25% of their sc…

This study is testing whether a medication called dupilumab can help regrow hair in children and teenagers with moderate-to-severe alopecia areata, an autoimmune condition that causes hair loss. About 76 participants, aged 6 to 18, will receive either the drug or a placebo via in…

This program provides early access to the investigational drug ritlecitinib for patients with severe alopecia areata who have lost at least 50% of their scalp hair. It's designed for people who haven't responded well to or can't tolerate other standard treatments available in the…

This study is testing if the drug ruxolitinib can help regrow hair in people with a rare immune system disorder called APECED who have severe hair loss (alopecia areata). About 70 participants, aged 12 to 65, will take the drug as a pill twice a day for 8 months. Researchers will…

This early-stage study is testing a new way to deliver a medication called cyclosporine directly into bald patches caused by alopecia areata, an autoimmune hair loss condition. The goal is to see if localized injections are safe and can help regrow hair while avoiding the side ef…

This study is testing an investigational medicine called LAD603 for adults with severe to very severe alopecia areata, an autoimmune condition causing significant hair loss. Participants will receive either LAD603 or a placebo injection to see if the drug helps hair regrow on the…

This study is testing an investigational pill called deuruxolitinib to see if it can help regrow hair in teenagers (ages 12-18) who have lost at least half of their scalp hair due to alopecia areata. For the first 24 weeks, participants will be randomly assigned to receive either…

This study is testing which solution works best when combined with a skin-pricking technique (microneedling) to help regrow hair in people with patchy alopecia areata. Researchers will compare a common steroid treatment against lactic acid and vitamin D3 solutions, with a fourth …

This large, late-stage study is testing whether a daily pill called upadacitinib can help regrow hair in people with severe alopecia areata, an autoimmune condition that causes patchy or total hair loss. About 1500 participants, including teens and adults, will take either the ac…

This study aims to see how well the already-approved drug ritlecitinib works for people with the autoimmune hair loss condition alopecia areata in real-world, everyday medical practice. It will follow 850 patients aged 12 and older who are prescribed the drug by their doctor to m…

This study is testing whether a higher dose (100 mg) of the medication ritlecitinib is safe and works better than the standard 50 mg dose for treating severe alopecia areata, a condition that causes significant hair loss. It will involve about 550 participants aged 12 and older w…

This study is collecting information from 5,000 adults with alopecia areata (an autoimmune hair loss condition) who are already being treated by a dermatologist. The goal is to track the long-term safety and effectiveness of real-world treatments over time. Researchers will follo…

This study aims to understand how three skin conditions—alopecia areata (hair loss), vitiligo (skin depigmentation), and hidradenitis suppurativa (painful skin lumps)—affect people's daily lives and quality of life. It will survey nearly 2,800 adolescents and adults with moderate…

This study aims to learn about the real-world safety and effectiveness of treatments for severe hair loss (alopecia areata) in teenagers. It will follow 1,500 adolescents aged 12-17 who are receiving standard care from their dermatologists. Researchers will collect information on…

This study is creating a large registry of patients with conditions like eczema, psoriasis, and alopecia areata to track how treatments work in real-world settings. Researchers will follow 15,000 adults and children over time to understand treatment safety, effectiveness, and how…